Raleigh, United States, September 1st, 2026, FinanceWire

Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities

Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties.

The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring’s Rebyota and Clenpiq, respectively – two synergistic, revenue-generating, FDA-approved GI drugs

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately $16.9 million in 2025 U.S. net sales

Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated $20.6 million in U.S. 2025 net sales with minimal promotion 

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals (“Ferring”), as part of Ferring’s ongoing strategic refocusing.

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “We have executed a clear strategic sequence. We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill’s experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products.” Mr. Ben-Asher added: “We thank Ferring for a smooth process to date and look forward to a successful collaboration.”

Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12 million, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.

“Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts,” said Rick Scruggs, RedHill’s Chief Commercial Officer. “Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered $20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories.”

C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI, with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences, indicating the need for use of prevention strategies.

Rebyota’s one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI. An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence.

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations – with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.

Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23m lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12m (21%) lives with preferred position5.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About RedHill Biopharma  

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of such sale; the expected benefits of the acquisition of commercialization rights to Rebyota and Clenpiq, the anticipated commercial growth and cash contribution from these products, expectations regarding market share growth, anticipated payer coverage, the Company’s strategic repositioning and path to operational profitability, potential use of milestone and royalty payments, and the Company’s ability to successfully commercialize Rebyota and Clenpiq. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. 

[i] Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.

[ii] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913. PMID: 25714160; PMCID: PMC10966662.

[iii] Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023 Mar 7;23(1):132. doi: 10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.

[iv] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538. doi:10.1007/s40265-022-01797-x.

[v] Data on file. Ferring Pharmaceuticals

[vi] MarketScan Commercial Claims and Encounters and Medicare Supplemental database

Contact

Chief Corporate and BD Officer
Adi Frish
RedHill Biopharma
adi@redhillbio.com

Somerville, Massachusetts, USA, September 1st, 2026, FinanceWire

RISE Robotics, a developer of electric actuation technology for heavy machinery and defense applications, today announced that it has been awarded a $100,000 START Grant from MassVentures, a competitive, non-dilutive program of the Commonwealth of Massachusetts supporting the commercialization of advanced technologies. As a Stage I awardee, RISE is also eligible to compete for up to $800,000 in total START funding as it advances through subsequent stages of the program.

The award provides additional support for RISE’s efforts to expand commercialization of its Beltdraulic technology. Beltdraulic is a high-force electric actuation system designed to replace traditional hydraulic systems with a fluid-free architecture, delivering hydraulic-class force with greater digital control, improved efficiency, and precision.

Hydraulics have been a foundational technology in heavy machinery for decades, powering equipment ranging from construction machinery to agricultural and industrial systems. RISE is developing an alternative architecture based on electric motors, belts, and pulleys that is designed to deliver high force without hydraulic fluid.

The MassVentures START award adds to RISE’s growing track record of government-backed technology development.

In February 2026, RISE received a $3 million U.S. Air Force Tactical Funding Increase (TACFI) award to advance SuperJammer, its fluid-free munitions handling system, toward testing and evaluation. SuperJammer applies RISE’s electric actuation technology to demanding defense environments where precision, reliability, and the elimination of hydraulic fluid can provide significant advantages.

The two programs support complementary stages of RISE’s commercialization strategy. The Air Force award supports development and productization of the technology for defense applications, while the MassVentures START Grant supports efforts to translate the underlying technology into broader commercial markets.

“This award is a strong validation of the progress we’ve made translating advanced engineering into real-world systems,” said Hiten Sonpal, CEO of RISE Robotics. “Massachusetts continues to be an important partner in helping companies like ours move from breakthrough technology to commercial deployment.”

RISE is targeting the broader heavy machinery market, where the company estimates the opportunity at approximately $750 billion. Its Beltdraulic platform is designed to enable equipment manufacturers to replace conventional hydraulic systems with electric actuation while also creating a foundation for digital control, teleoperation, and autonomous operation.

RISE Robotics has generated more than $9 million in total revenue to date and is currently conducting a Regulation Crowdfunding offering that is open to both accredited and non-accredited investors.

About the MassVentures START Program

The START Grant Program, administered by MassVentures, provides non-dilutive funding to Massachusetts-based companies with active SBIR/STTR Phase II awards. The program is designed to help companies transition federally funded innovations toward commercialization, product development, and job creation within the Commonwealth.

About RISE Robotics

RISE Robotics is a deep technology company developing electric actuation systems for the heavy machinery and defense markets. Its flagship Beltdraulic technology uses a belt-and-pulley architecture to deliver high-force linear motion without hydraulic fluid.

RISE’s technology is designed to provide a pathway from conventional hydraulic systems to electric, digitally controlled machinery, with potential applications across construction, agriculture, industrial equipment, and defense.

RISE has generated more than $9M in total revenue and is a Reg CF company, allowing both accredited and non-accredited investors to own a piece of its innovative technology.

riserobotics.com

Contact

Lauren Damon
RISE Robotics
lauren@riserobotics.com
(617) 863-2521

Program is part of DrivePoint’s efforts to strengthen Colorado’s professional driver pipeline and build Colorado’s next generation of professional drivers and transportation professionals.

United States, 1st Sep 2026—DrivePoint CDL Academy, a Denver-based training and testing facility for commercial driver’s licenses (CDL), today announced the launch of its Transportation Workforce & Safety Initiative. The initiative trains future commercial vehicle operators in safety skills that go beyond driving-related requirements. The goal is to augment Colorado’s pipeline of professional drivers, which is currently shrinking, and build Colorado’s next generation of professional drivers and transportation professionals.

“At DrivePoint, our mission extends beyond CDL training,” said Alisha Brown. “We believe professional drivers play a vital role in our communities, economy, and public safety. Through workforce development, safety leadership, and community engagement, we are committed to supporting the next generation of transportation professionals.”

The initiative supports career pathways into transportation and commercial driving, promoting transportation careers as stable, high-demand professions in the process. It provides training opportunities for career changers, veterans, women, and individuals entering the transportation industry. The initiative works by partnering with employers to develop safer and more qualified drivers. By so doing, the initiative will help address workforce shortages in trucking, utilities, municipalities, passenger transportation, and fleet operations.

“Transportation is essential infrastructure,” Brown added. “Most people don’t even realize how much their communities rely on skilled drivers to keep goods, utilities, public services, and people moving. As the industry struggles with a shortage of trained professionals, we are all going to feel the effects soon. Our initiative intends to avert problematic outcomes.”

Safety leadership is one of the initiative’s core objectives. As Brown put it, “Professional driver training is about far more than passing a test. It is about creating a culture of safety.” To this end, the initiative emphasizes risk awareness, training students to perform thorough vehicle inspections and reinforcing the importance of brake safety, cargo securement, and compliance.

Brown added, “We support employers in building safer fleets and reducing preventable incidents. By encouraging professionalism and accountability in the transportation industry, we are fielding graduates who contribute to safer roads for everyone, including families, commuters, emergency responders, and fellow motorists.”

DrivePoint invites employers, workforce development organizations, municipalities, community partners, and aspiring transportation professionals to join the conversation about building a stronger, safer transportation workforce for Colorado.

For more information, visit www.drivepointcdlacademy.com

About DrivePoint CDL Academy

DrivePoint CDL Academy is a Colorado-based and family-owned business that specializes in commercial driver license (CDL) training that includes city driving and mountain driving preparation because real-world readiness means being prepared for every terrain. Its programs are designed to meet industry standards while also focusing on what matters most: safety, professionalism, and long-term success behind the wheel.

Media Contact

Organization: DrivePoint CDL Academy

Contact Person: Alisha Brown

Website: https://www.drivepointcdlacademy.com

Email: Send Email

Country:United States

Release id:48652

The post DrivePoint CDL Academy Launches Transportation Workforce & Safety Initiative appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section